Shots:

• GSK to acquire Tesaro- in all stock transaction with its Zejula and preclinical candidates. Tesaro to get $75/share in cash for a premium of 62% with total deal value of $5.1B
• The focus of acquisition is to build oncology portfolio with Tesaro’s products for targeting multiple cancers including ovarian- lung and prostate cancer. In March 2015- GSK divested its oncology portfolio related R&D activities- AKT inhibitor rights and commercialization partner rights to Novartis
• Zejula (niraparib) PO is a poly ADP ribose polymerase (PARP) inhibitor for ovarian cancer and is approved for adults with recurrent ovarian cancer + Pt-based CT in the US and EU in 2017

Ref: GSK | Image: GSK